Dr. Waltzman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Molecular Templates
185 Hudson Street, Suite 1510
Jersey City, NJ 07311Phone+1 862-204-4860- Is this information wrong?
Education & Training
- Columbia Business SchoolMBA, Business, 2004 - 2006
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
- The Warren Alpert Medical School of Brown UniversityClass of 1992
Certifications & Licensure
- CA State Medical License 1998 - 2026
- NY State Medical License 1995 - 2026
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 278 citationsLXR/ApoE Activation Restricts Innate Immune Suppression in CancerMasoud Tavazoie, Ilana Pollack, Raissa Tanqueco, Benjamin N. Ostendorf, Bernardo S. Reis, Foster C. Gonsalves, Isabel Kurth, Celia Andreu-Agullo, Mark L. Derbyshire, J...> ;Cell. 2018 Feb 8
- 1272 citationsJAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.Claire N. Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Roger J. Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S. Hunter, Richar...> ;The New England Journal of Medicine. 2012 Feb 29
- Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myel...Harrison CN, Kiladjian J, Al-Ali HK, Gisslinger H, Waltzman RJ, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Cervantes F, Vannucchi AM, Barbui T, Barosi G> ;J. Clin. Oncol.. 2011-06-20
- Join now to see all
Press Mentions
- EPS for Molecular Templates, Inc. (MTEM) Expected at $0.16March 7th, 2019
- Rgenix Treats First Patient in Phase 1 Trial of RGX-202October 31st, 2018
- Rgenix Bags $40M to Advance Cancer Drugs, Including GSK CastoffOctober 9th, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: